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Abstract
Endothelin 1 (ET-1) is a key regulator of vascular homeostasis. We have recently reported that the presence of Human
antigen class I, HLA-B35, contributes to human dermal microvascular endothelial cell (HDMEC) dysfunction by upregulating
ET-1 and proinflammatory genes. Likewise, a Toll-like receptor 3 (TLR3) ligand, Poly(I:C), was shown to induce ET-1
expression in HDMECs. The goal of this study was to determine the molecular mechanism of ET-1 induction by these two
agonists. Because HLA-B35 expression correlated with induction of Binding Immunoglobulin Protein (BiP/GRP78) and
several heat shock proteins, we first focused on ER stress and unfolded protein response (UPR) as possible mediators of this
response. ER stress inducer, Thapsigargin (TG), HLA-B35, and Poly(I:C) induced ET-1 expression with similar potency in
HDMECs. TG and HLA-B35 activated the PERK/eIF2a/ATF4 branch of the UPR and modestly increased the spliced variant of
XBP1, but did not affect the ATF6 pathway. Poly(I:C) also activated eIF2a/ATF4 in a protein kinase R (PKR)-dependent
manner. Depletion of ATF4 decreased basal expression levels of ET-1 mRNA and protein, and completely prevented
upregulation of ET-1 by all three agonists. Additional experiments have demonstrated that the JNK and NF-kB pathways are
also required for ET-1 upregulation by these agonists. Formation of the ATF4/c-JUN complex, but not the ATF4/NF-kB
complex was increased in the agonist treated cells. The functional role of c-JUN in responses to HLA-B35 and Poly(I:C) was
further confirmed in ET-1 promoter assays. This study identified ATF4 as a novel activator of the ET-1 gene. The ER stress/
UPR and TLR3 pathways converge on eIF2a/ATF4 during activation of endothelial cells.
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Introduction
Endothelin-1 (ET-1) is a potent vasoconstrictor and one of the
key regulators of vascular homeostasis. ET-1 dysfunction is
associated with a number of pathological conditions including
hypertension, atherosclerosis, cardiovascular disorders, and cancer
[1,2,3]. Under physiological conditions, ET-1 is produced in small
amounts mainly in endothelial cells (ECs). However in patho-
physiological conditions, its production is stimulated in a large
number of different cell types, including endothelial cells, vascular
smooth muscle cells, cardiac myocytes, and inflammatory cells
such as macrophages and leukocytes. In addition to its main role as
a vasoconstrictor, ET-1 also contributes to inflammation, as well as
fibrosis during various pathophysiological processes.
Extensive studies of ET-1 gene expression have led to
characterization of the signaling pathways and transcription
factors involved in its regulation [4,5]. A complex network
consisting of the common and tissue specific transcription factors
responding in the coordinated fashion to physiological and
pathological stimuli have been shown to regulate ET-1 expression
in a cell type and context specific manner. One of the main
regulatory factors is a FOS/JUN complex that binds to an
activator protein 1 (AP-1) response element located at a -108 bp in
the ET-1 promoter region. This site mediates upregulation of the
ET-1 gene by phorbol esters, Angiotensin II, Thrombin, and
High-density lipoprotein (HDL), which stimulate AP-1 in a Protein
kinase C (PKC)-dependent manner. On the other hand, Leptin
activates AP-1 through the Jun N-terminal kinase (JNK) and
extracellular-signal-regulated kinases 1/2 (Erk1/2) pathways. AP-1
in cooperation with GATA-binding factor 2 (GATA2) is also
required for the basal transcription of the ET-1 gene in endothelial
cells, while other members of the GATA family regulate ET-1
expression in other cell types. Additional important transcription
binding sites include hypoxia response element, Hypoxia-inducible
factors (HIF-1), transforming growth factor b (TGF-b)/Smad
response element, which have been also described to cooperate
with AP-1 to induce ET-1 [6], as well as the Nuclear factor kB
(NF-kB) binding site that mediates responses to inflammatory
cytokines. Other cell type specific response elements have also
been characterized [7].
Endoplasmic Reticulum (ER) stress is defined as accumulation
of unfolded or misfolded proteins in the ER, triggering an adaptive
program called the unfolded protein response (UPR). The UPR
alleviates ER stress by suppression of protein synthesis, facilitation
of protein folding via induction of ER chaperones, and reinforced
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degradation of unfolded proteins. Three major transmembrane
transducers of ER stress have been identified in the ER. Those are
the RNA-dependent protein kinase-like ER kinase (PERK),
activating transcription factor 6 (ATF6), and inositol-requiring
ER-to-nucleus signal kinase 1a (IRE1a). Activation of PERK leads
to phosphorylation of the eukaryotic translation initiation factor 2a
(eIF2a), causing general inhibition of protein synthesis. In response
to ER stress, ATF6 transits to the Golgi where it is cleaved by the
proteases Site-1 protease (S1P) and Site-2 protease (S2P), yielding
a free cytoplasmic domain which functions as an active
transcription factor. Similarly, activated IRE1a catalyzes removal
of a small intron from an X-box-binding protein 1 (XBP1) mRNA.
This splicing event produces an active transcription factor XBP1.
If the cell fails to deal with the protein-folding defect and restore
homeostasis, a pro-apoptotic CCAAT/2enhancer-binding pro-
tein homologous protein (CHOP)-mediated pathway is initiated
[8].
There is extensive evidence that ER stress/UPR is closely linked
to the inflammatory pathways through activation of the two key
inflammatory mediators, JNK and NF-kB [8,9] Recent studies
have also revealed that UPR and innate immune pathways share
common mediators [10,11]. It was shown that stimulation of the
Toll-like receptor (TLR) 2 or TLR4 leads to selective activation of
the IRE1a/XBP1 pathway, contributing to the optimal and
sustained production of proinflammatory cytokines in macro-
phages [12]. However, activation of the IRE1a/XBP1 pathway by
these TLR agonists did not lead to expression of the genes typically
regulated by these mediators during ER stress, suggesting an
alternative utilization of the components of the UPR pathways.
The specific mechanisms involved in these atypical responses are
still not well understood and require further investigation.
We have recently shown that ectopic expression of HLA-B35,
an antigen associated with SSc in Choctow Indians [13] and SSc-
PAH in Italian patients [14,15], led to a significant increase of ET-
1 and a decrease of eNOS in cultured endothelial cells (ECs) [16].
In addition to ET-1, we have also observed upregulation of
interferon-regulated genes and other inflammatory genes in ECs
expressing HLA-B35. Furthermore, expression of HLA-B35, but
not a control antigen HLA-B8, potently upregulated several
cellular chaperones including BiP, HSP70 and HSP40, suggesting
an activation of ER stress/UPR in these cells. However, other
UPR genes such as ERO1 (ER oxidoreductin 1), and PDI (protein
disulphide isomerase), which are involved in oxidative protein
folding, as well as a pro-apoptotic UPR mediator, CHOP were not
upregulated, consistent with activation of an adaptive phase of the
UPR. Relevant to these findings Farina et al have reported
upregulation of ET-1 in response to a synthetic analog of dsRNA,
Poly(I:C), in dermal endothelial cells and fibroblasts [17]. Given
the recently uncovered cross-talk between the UPR and the innate
immune pathways, the goal of this study was to further investigate
whether common mediators are involved in ET-1 gene regulation
in response to these stimuli. Here we report that induction of ER
stress or stimulation with Poly(I:C) activate the eIF2a-ATF4
pathway and promote formation of the ATF4/c-JUN complexes.
This protein complex in concert with the NF-kB pathway activates
ET-1 gene transcription in endothelial cells.
Materials and Methods
Reagents
Thapsigargin (TG) was purchased by Sigma-Aldrich (St. Louis,
MO). Poly(I:C) was purchased by InvivoGen (San Diego, CA).
Tissue culture reagents, EBM kit by Lonza (Walkersville, MD).
The protease inhibitor cocktail set III and phosphatase inhibitor
cocktail set II were purchased from Calbiochem (San Diego, CA).
Enhanced chemiluminescence reagent and bicinchoninic acid
protein assay reagent were obtained from Pierce Chemical Co.
(Rockford, IL). TRI Reagent was purchased from the Molecular
Research Center Inc. (Cincinnati, OH).
For western blot, antibodies were used as followed: goat ATF4
and rabbit ATF6 (Santa Cruz Biotechnology, Santa Clara, CA) at
a 1:500 dilution; rabbit pPERK and PERK (Santa Cruz
Biotechnology, Santa Clara, CA) at a 1:500 dilution, rabbit p-
eIF2a and mouse eIF2a Ab (Santa Cruz Biotechnology, Santa
Clara, CA) at 1:500 dilution; rabbit cJun and rabbit NF-kBp65 Ab
(Santa Cruz Biotechnology, Santa Clara, CA) at a 1:500 dilution;
monoclonal b-actin Ab (Sigma-Aldrich) at 1:5000 dilution and
mouse Lamin A/C at 1:1000 dilution.
Cell Culture
Human dermal microvascular endothelial cells (HDMECs) were
isolated from human foreskins using the protocol of Richard et al
[18]. Upon informed consent and in compliance with the
Institutional Review Board of Human studies, written approval
was obtained from Perinatal Committee (IRB number H-29190)
of Boston University Medical School. Briefly, primary cultures of
human foreskins were established after the removal of epidermis.
Such cultures consist of a mixture of HDMECs, dermal
fibroblasts, and some keratinocytes. Subconfluent cultures were
treated with tumor necrosis factor-a for 6 h to selectively induce
the expression of E-selectin in HDMECs. HDMECs were then
purified using magnetic beads coupled to an anti-E-selectin
monoclonal antibody. First passage cultures usually consist of
.99% HDMECs. A second immunomagnetic purification step
ensures homogenous population of HDMECs suitable for long
term culturing. Purity of the HDMEC cultures was evaluated
using anti-CD31 and anti-von Willebrand factor antibodies. These
cells were cultured on collagen-coated 6-well plate in EBM
medium supplemented with 10% FBS, EC growth supplement
mix at 37uC under 5% CO2 in air. The culture medium was
changed every other day. HDMECs harvested between passage 2
and 6 were used for experiments.
Adenoviral Constructs
An adenoviral vector expressing HLA-B35 (or Ad-B8) and
control green fluorescent protein (Ad-Go) were generated as
described earlier [18]. The dose used to transduce human dermal
microvascular endothelial cells was 10 multiplicities of infection of
the adenovirus (MOI). ECs grown in a 6-well dish were transduced
with Ad (Ad-B35/GFP, -B8/GFP, and -GFP), after 48 h cells were
collected for RNA analyses or for Western blot.
Real-time PCR
Total RNA was extracted using the guanidiniumthiocyanate-
phenol-chloroform method, concentration and purity was de-
termined by measuring OD at 260 and 280 nm using a spectro-
photometer. RNA was reversibly transcribed by aid of the first-
strand cDNA Synthesis Kit for RT-PCR (Roche Applied Science,
Indianapolis, IN). To avoid amplification from traces of possible
DNA contamination in the RNA isolation, PCR primers were
designed to span introns. All primers were checked for specificity
by Blast search. Real-time RT-PCR was performed using IQ
SYBR Green Supermix (Bio-Rad, Hercules, CA) and MyiQ
Single-Color Real-Time PCR Detection System (Bio-Rad). The
amount of template used in the PCR reactions was cDNA
corresponding to 200 ng reverse-transcribed total RNA. DNA
polymerase was first activated at 95uC for 3 min, denatured at
95uC for 30 s, and annealed/extended at 61uC for 30 s, for 40
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cycles according to the manufacturer’s protocol. Expression of the
housekeeping gene b-actin served as an internal positive control in
each assay performed. After measurement of the relative
fluorescence intensity for each sample, the amount of each mRNA
transcript was expressed as a threshold cycle value. The primers
are listed in Table 1.
Immunofluorescence Staining on Adherent Cell Cultures
Cultured HDMECs grown on collagen-coated cover slips were
transduced with Adenovirus carrying HLA-B35 (Ad-B35/GFP),
Ad-B8/GFP and Ad-G0/GFP (virus control) for 48 hours.
Treated cells were fixed with 4% paraformaldehyde for 15
minutes followed by incubation with 0.15 M Glycine for 30 min.
Non-specific protein binding was blocked with 3% BSA for 1 h.
Next, cells were incubated at 4uC overnight with primary mouse
monoclonal MHC class I Ab (W6/32) (Santa Cruz Biotechnology,
Santa Clara, CA) at a 1:500 dilution. After washing, cell cultures
were incubated with Alexa fluor 594 donkey anti-mouse (Invitro-
gen, Grand Island, NY) antibody for 1.5 h. Cells were mounted on
slides using Vectashield with DAPI (Vector Laboratories, Burlin-
game, CA) and examined using a FluoView FV10i confocal
microscope system (Olympus, Center Valley, PA) at 488 nm
(green), 594 nm (red) and 405 nm (blue).
Western Blot Analysis
Cells were collected and washed with PBS. Cell pellets were
suspended in lysis buffer containing 20 mM Tris-HCl, pH 7.5,
15 mM NaCl,1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate, and 1 mM glycerophosphate
with freshly added phosphatase inhibitors (5 mM sodium fluoride
and 1 mM Na3VO4) and a protease inhibitor mixture (Sigma-
Aldrich). Protein concentration was quantified using the BCA
Protein Assay kit (Pierce). Equal amounts of total proteins per
sample were separated via SDS-PAGE and transferred to
nitrocellulose membranes (Bio-Rad). Membranes were blocked
in milk in TBST overnight at 4uC and probed with primary Ab
overnight at 4uC. After TBST washes, membranes were probed
with HRP-conjugated secondary Ab against the appropriate
species for 1–2 h at room temperature. Protein levels were
visualized using ECL reagents (Amersham Biosciences, Piscat-
away, NJ).
ET-1 Bio-assay
The ET-1 bioassay was performed according to the protocol
supplied with the kit from Assay Designs (cat no. 900-020A).
Standards and samples were incubated in supplied pre-coated 96-
well plate, washed, incubated with horse radish peroxidase labeled
anti- ET-1 antibody and washed again before adding the provided
TMB substrate and measuring the absorbance.
siRNA Experiments
HDMECs were trasfected with either siRNA specific to human
ATF4 (ON-TARGET plus SMARTpool, Dharmacon RNA
Technologies, CO), PKR (Santa Cruz biotechnology, CA) or
negative-control siRNA (Qiagen, Chatsworth, CA) at concentra-
tion of 20 nM using HiPerfect reagent (Qiagen) according to the
manufacturer’s protocol. After 48 hours, RNA was extracted and
Real-time PCR was performed.
Inhibitor Experiment
HDMECs were incubated in the presence of the 25 nM of JNK
SP600125 or NF-kB SN50 inhibitor (Enzo Life Sciences, Farm-
ingdale, NY) for 3 hours before treatment. After 48 hours, RNA
and protein were extracted.
Co-Immunoprecipitation
Cell lysates were prepared after appropriate treatment in
radioimmune precipitation buffer. For immunoprecipitation of
cJUN (or NF-kB p65), antibody was added to 300 mg of
precleared cell lysate, and complex formation was carried out at
4uC overnight. The protein-antibody complexes were recovered
using protein G-Sepharose beads for 2 h at 4uC. The immuno-
precipitates were washed four times in radioimmune precipitation
buffer, eluted by boiling for 5 min in 26SDS sample buffer, and
analyzed by Western blot with anti-ATF4 antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA).
Plasmids, Transient Transfections and Luciferase Assay
Luciferase reporters driven by 2650-bp and 2193-bp frag-
ments (representing the wildtype and mutated AP-1 site) of the
human ET-1 promoter described previously 1. Transient transfec-
tions of promoters were performed in HDMECs seeded into 6-well
plates using Fugene6 (Roche Applied Science) according to the
manufacturer’s instructions. After overnight incubation, cells were
treated and then further incubated for 24 h. The cells were
harvested and assayed for luciferase reporter activity using the
Promega luciferase assay kit according to the manufacturer’s
instructions. Promoter/reporter plasmids were cotransfected with
pCMV-bGal (Clontech), which was used to adjust for differences
in transfection efficiencies between samples. Cells were harvested
Table 1. Primer sequences for quantitative PCR.
Forward Reverse
Human-PPET-1 59-gctcgtccctgatggataaa-39 59-ccatacggaacaacgtgct-39
Human-ATF4 59-tggctggctgtggatgg-39 59-tcccggagaaggcatcct-39
Human-ATF6 59-ttttagcccgggactctttc-39 59-tcagcaaagagagcagaatcc-39
Human-XBP1u 59-ccttgtagttgagaaccagg-39 59-gggcttggtatatatgtgg-39
Human-XBP1s 59-ggtctgctgagtccgcagcagg-39 59-gggcttggtatatatgtgg-39
Human-PKR 59-tgttgggatggatttgattatg-39 59-gaaaaggcacttagtctttgacct-39
Human-bactin 59-aatgtcgcggaggacctttgattgc-39 59-aggatggcaagggacttcctgtaa-39
Mouse-ATF4 59-gagcttcctgaacagcgaagtg-39 59-tggccacctccagatagtcatc-39
Mouse-bactin 59-ctaaggccaaccgtgaaaag-39 59-accagaggcatacagggaca-39
doi:10.1371/journal.pone.0056123.t001
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and Luciferase activity of the promoter was assayed using Promega
Luciferase assay kit. Values given are means 6 standard errors of
triplicate assays from three individual experiments.
In vivo Administration of Poly(I:C)
C57Bl/6 WT and C57Bl/6 TICAM/TRIF 2/2 mice were
obtained from The Jackson Laboratory; C57Bl/6 IFNAR12/2
mice were provided by Dr John Sprent. All of the experiments
were performed under the guidelines of the Boston University
Institutional Animal Care and Use Committee. Osmotic pumps
designed to deliver Poly(I:C) (0.5 mg/ml in PBS, 0.1 mg total dose
in 200 ml released over 7 days, Alzet) or PBS were implanted
subcutaneously on the back in 6–10-weekold mice. After 7 days
mice were killed and skin (,1 cm2) surrounding the pump outlet
was homogenised in Trizol for preparation of RNA, then minced
and disrupted using a Polytron homogeniser and processed
according to the manufacturer’s protocol.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Boston University (Permit Number: AN-
14942.2012.01). All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to minimize
suffering.’’.
Immunostaining
Skin sections biopsies from healthy individuals and limited
cutaneous systemic sclerosis (lcSSc) patients including 8 patients
with pulmonary arterial hypertension (lcSSc-PAH) based on
echoradiography and right heart catheterization and 11 patients
without PAH (lcSSc-noPAH) and 5 healthy controls were provided
by the Boston University Core Centers (http://www.bu.edu/
sscores/); IRB: H31–506. Patient information is included in
Table 2. Immunohistochemistry was performed on formalin-fixed,
paraffin-embedded tissue sections using a Vectastain ABC kit
(Vector Laboratories, Burlingame, CA) according to the manu-
facturer’s instructions. Briefly, 8-micrometer-thick sections were
mounted on APES (amino-propyl-triethoxy-silane)-coated slides,
deparaffinized with Histo-Clear (National diagnostic, Atlanta GA),
and rehydrated through a graded series of ethanol. Endogenous
peroxidase was blocked by incubation in 0.3% hydrogen peroxide
for 15 minutes and incubated with blocking buffer for 1 hour. The
sections were then incubated overnight at 4uC with antibody
against ATF4 (Abcam, Cambridge, MA) diluted 1:500 in blocking
serum, followed by the incubation with secondary antibody. The
Table 2. Clinical and hemodynamic data of study subjects.
Sample Age Gender
Disease
Duration PAP PCWP PASP Treatment ATF4 staining
Normal 11-6 30 M ++
Normal 11-7 24 M +
Normal 11-8 47 F ++
Normal 12-1 25 M 2
Normal 12-2 25 F +
lcSSc PAH 12-8 65 F 16 years 1 month 49 30 44 no medications 2
lcSSc PAH 12-7 58 M 16 years 30 12 65 no medications ++
lcSSc PAH 12-6 69 F 16 years 54 5 71 no medications ++
lcSSc PAH 12-3 75 F 25 years 48 9–10 62 sildenafil +
lcSSc PAH 12–17 30 F 1 years 8 months 25 2 N/A cell cept revatio +
lcSSc PAH 12–20 60 F 3 years 25 2 N/A prednisone +++
lcSSc PAH 12–18 59 F 15 years N/A N/A N/A none +
lcSSc PAH 12–19 52 F 25 years N/A N/A N/A viagra ++
lcSSc NoPAH 12–27 59 M 45 none +
lcSSc NoPAH 12-2 65 F 10 years myocophenolate +
lcSSc NoPAH 12-10 40 F 2 years none ++
lcSSc NoPAH 12-1 58 F 2 years prednisone, mycophenolate 2
lcSSc NoPAH 12–35 56 F 8 years 33 none +
lcSSc NoPAH 12–31 61 F 14 years hydroxychloroquine +
lcSSc NoPAH 12–28 65 F 6 months 25 none 2
lcSSc NoPAH 12–25 67 M 7 years 25 none +
lcSSc NoPAH 12–10 40 F 2 years cyclophosphamide ++
lcSSc NoPAH 12–13 39 F 1 year cytoxan +
lcSSc NoPAH 12–21 20 F 6 years none ++
PAP=pulmonary artery pressure. PCWP=pulmonary capillary wedge pressure. PASP = pulmonary artery systolic pressure.
2 indicates no staining or little staining in ,10% of the cells.
+ indicates faint, partial staining in .20% of the cells.
++ indicates light to moderate stain in .50% of the cells.
+++ indicates bright staining in .50% of the cells.
doi:10.1371/journal.pone.0056123.t002
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concentration of primary antibody was first tested to determine the
optimal sensitivity range. The immunoreactivity was visualized
with diaminobenzidine (Vector laboratories, Burlingame, CA) and
the sections were counterstained with hematoxylin.
Statistical Analysis
Student’s t test analysis was performed to determine statistical
significance. Values less than or equal to 0.05 were considered
statistically significant. All experiments were repeated at least three
times using independently isolated endothelial cell cultures.
Results
ER Stress and Poly(I:C) Activate Common ER Stress/UPR
Pathways in HDMECs
In the initial experimentwecompared theeffects ofHLA-B35with
a known ER stress inducer, thapsigargin (TG), and a TLR3 agonist,
Poly(I:C), on the expression of ET-1 mRNA and protein in primary
dermal microvascular endothelial cells (HDMECs). HLA-B35 was
expressed using adenoviral delivery as previously described [16]. To
control for the presence of adenoviral genes we used adenovirus
expressing a closely related antigen, HLA-B8, as well as an empty
virus. As shown in Fig. 1a,HLA-B35 and Poly(I:C) upregulated (pre-
pro-endothelin-1)PPET-1mRNAlevelswithasimilarpotency7-fold
60.58,p = 0.05vs8-fold60.25,p = 0.05, respectively,whileTGwas
a stronger inducer of PPET-1 (26-fold60.75, p =0.001). Ad-HLA-
B8, as well as an empty virus vector (data not shown) did not affect
PPET1 mRNA expression. To verify that the increase in PPET-1
mRNA corresponds to an increase of the bioactive 21-aa ET-1
peptide, we measured levels of ET-1 protein in supernatants of Ad-
B35 (and Ad-B8), TG and TLR ligand-treated ECs. Consistent with
themRNAmeasurementsERstress inducers increasedET-1protein
levels (Ad-B35, 3.5-fold60.6, p = 0.05 and TG, 5.3-fold60.80,
p = 0.05). Similarly, Poly(I:C) induced ET-1 protein by 3.7-
fold60.98 (Fig. 1b). PPET-1 mRNA expression was further
enhanced by a combination of HLA-B35, and to a lesser degree
TG, and Poly(I:C) (Fig. 1c).
To further determine if HLA-B35 mediates its effects via
peptide binding to the antigen-binding groove we utilized mouse
monoclonal anti-MHC class I blocking antibody (W6/32).
Figure 1. HLA-B35, TG, and Poly(I:C) upregulate ET-1 mRNA and protein in HDMECs. Upregulation of PPET-1 mRNA after HLA-B35 (or HLA-
B8), TG, or Poly(I:C) treatments alone (a) or in combination (c) in HDMECs. Confluent dishes of HDMECs were transduced with 10 MOI of Adenovirus
encoding HLA-B35/GFP (Ad-HLA-B8/GFP) for 48 h or treated with 10pM TG, or 2.5 mg/ml Poly(I:C) for 24 hours. Total RNA was extracted and mRNA
levels of PPET-1 were quantified by quantitative RT-PCR. Expression of the housekeeping gene b-actin served as an internal positive control in each
assay performed. After measurement of the relative fluorescence intensity for each sample, the amount of each mRNA transcript was expressed as
a threshold cycle value. (b) Bioactive 21-aa ET-1 peptide in HDMECs after Ad-B35/GFP (Ad-B8/GFP), TG, or Poly(I:C) treatment. ET-1 protein was
measured by ELISA in the supernatants. The average protein concentration for each group is represented as a bar 6 SE. *p = 0.05; **p = 0.001 (d)
Immunofluorescence was performed using mouse monoclonal MHC class I Ab (W6/32) in HDMECs transduced with HLA-B35 (Ad-B35/GFP), Ad-B8/
GFP and Ad- G0/GFP (virus control). Left column DAPI, middle column GFP, right column HLA. Bar: 100 mm.
doi:10.1371/journal.pone.0056123.g001
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HDMECs transduced with Ad-HLA-B35/GFP and HLA-B8/
GFP for 24 hours were treated with increasing dose of W6/32
(0.1–10 mg/ml) for the following 24 hours. Treatment with
antibody did not affect ET-1 mRNA levels, suggesting that
HLA-B35 does not modulate ET-1 through peptide binding to the
antigen-binding groove (supplemental data, Fig. S1). To determine
subcellular localization of ectopic HLA-B35 we performed
immunofluorescence staining using HDMECs transduced with
Ad-HLA-B35/GFP, Ad-HLAB8/GFP and Ad-G0/GFP (virus
control) for 48 hours. Spotty positive staining was observed in the
cytoplasm primarily around the nucleus, suggesting ER retention
of the HLA-B35 and HLA-B8. Together, these data suggest that
HLA-B35 is primarily retained in the ER, where it might induce
ER stress and UPR. Interestingly, although HLA-B8 displayed
a similar cellular distribution, expression of HLA-B8 was not
associated with upregulation of BiP and other heat shock proteins
[18]. The specific structural determinants of HLA-B35 that may
explain its biological effects are currently not known.
To further characterize the nature of the HLA-B35-mediated
ER stress, we examined the effect of HLA-B35 (or HLA-B8), TG,
and Poly(I:C) on the mRNA expression of the three main UPR
mediators, transcription factors ATF4, ATF6 and XBP1. ATF4
mRNA levels were significantly increased in response to the HLA-
B35 and Poly(I:C) treatment, while TG was a less potent inducer
of ATF4 mRNA under this experimental conditions (Fig. 2a).
When Poly(I:C) was used in combination with the ER stress
inducers, a further upregulation of ATF4 mRNA was observed
(Fig. 2b). Furthermore, both HLA-B35 and TG moderately
increased spliced (active) form of the transcription factor XBP1
(XBP1s), while TLR3 had no effect on the XBP1 splicing (Fig. 2c).
In contrast, the expression level of ATF6 was not responsive to any
of these treatments in HDMECs (Fig. 2d).
Since nuclear translocation of ATF4 is indicative of its
activation status, we examined nuclear extracts for the presence
of ATF4 by western blot. Nuclear ATF4 was examined at various
time points (15 min. to 6 hours) after TG and Poly(I:C) treatments
and 24 hours post infection with HLA-B35 or HLA-B8
adenoviruses. Nuclear ATF4 was rapidly increased (15–30 min)
after TG and Poly(I:C) treatments (Fig. 3a and Fig. 3b). Likewise,
HLA-B35 markedly increased nuclear presence of ATF4 (Fig. 3c).
Furthermore, increased phosphorylation of the upstream activa-
tors of ATF4, PERK and eIF2a, was observed in response to these
treatments (Fig. 3, right panels). Consistent with the mRNA data,
nuclear levels of ATF6 remained unchanged. Together, these
results demonstrate that ATF4 is activated in a similar manner by
ER stress/UPR and Poly(I:C) in endothelial cells.
PKR Mediates Activation of the ET-1 Gene in Response to
Poly(I:C)
Protein kinase RNA-activated (PKR) is activated by dsRNA and
plays an important role in the IFN signaling [19]. Similar to
Figure 2. ER stress and Poly(I:C) activate selected ER stress/UPR pathways. ATF4 (a, b), XBP1 splicing (c) and ATF6 (d) mRNA levels in
HDMECs treated with HLA B35 (HLA-B8), TG, and Poly(I:C) alone or in combination. Confluent dishes of HDMECs were transduced with 10 MOI of Ad-
B35/GFP (or Ad- B8/GFP) for 48 h treated with 10pM TG, or 2.5 mg/ml Poly(I:C) for 24 hours. Total RNA was extracted and mRNA levels of transcription
factors were examined by quantitative RT-PCR. Expression of the housekeeping gene b-actin served as an internal positive control in each assay
performed. After measurement of the relative fluorescence intensity for each sample, the amount of each mRNA transcript was expressed as
a threshold cycle value. *p = 0.05; **p = 0.001.
doi:10.1371/journal.pone.0056123.g002
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PERK, activated PKR induces phosphorylation of eIF2a and
a subsequent ATF4 nuclear translocation. To clarify whether
activation of PKR is involved in the ET-1 upregulation by
Poly(I:C) treatment, we used siRNA approach to knock down
PKR. Initial experiments have established an optimal dose and
time for PKR siRNA to achieve maximal inhibition of the PKR
mRNA level. Treatment of HDMECs with 20 nM of PKR siRNA
for 48 hours resulted in depletion of PKR mRNA levels (around
50%) (Fig. 4a). Following 24 hour incubation with siRNA, cells
were treated with Poly(I:C) for additional 24 hours. Under these
conditions basal PPET-1 gene expression was downregulated by
the siRNA treatment, suggesting that PKR contributes, in part, to
the constitutive expression of ET-1 (Fig. 4b). Furthermore,
depletion of PKR almost completely abrogated Poly(I:C)-induced
stimulation of PPET-1 (Fig. 4b). Interestingly, depletion of PKR
upregulated phosphorylated eIF2a (Fig. 4c), as well as nuclear
ATF4 level (Fig. 4d) in unstimulated cells, suggesting that without
activation, PKR may negatively regulate this pathway. However,
in the Poly(I:C)-stimulated cells phosphorylation of eIF2a was
abrogated and the ATF4 nuclear level was markedly decreased.
These results suggest that PKR mediates ET-1 upregulation in
response to Poly(I:C) in HDMECs.
We next investigated whether ATF4 is involved in regulation of
ET-1 in the Poly(I:C)-treated mice. It has been previously reported
that mice receiving continuous Poly(I:C) injection through the
osmotic pump for 7 days showed highly increased expression of
ET-1 [17]. In addition, this response was abrogated in the TIR-
domain-containing adapter-inducing interferon b/Toll-interleukin
1 receptor domain (TIR)-containing adaptor molecule-1 (TRIF/
TICAM) deficient mice, and only partially inhibited in the
interferon-a/b receptor (IFNAR)-1 deficient mice, indicating that
ET-1 induction following Poly(I:C) stimulation is mediated by
TLR3. As shown in Fig. 4e, expression of ATF4 closely correlated
with the previously shown ET-1 expression in the Poly(I:C) treated
mice [16]. Increased expression of ATF4 mRNA was also
observed in the Poly(I:C) treated WT mice, but this response
was significantly decreased in the TRIF/TICAM2/2 mice [WT
Poly(I:C) vs TRIF/TICAM2/2 Poly(I:C) p = 0.001]. On the
other hand, depletion of IFNAR1 had only a modest, non-
significant inhibitory effect on the Poly(I:C)-induced ATF4 mRNA
level in comparison to WT mice. We next examined the
distribution of ATF4 protein in the mouse skin by immunohisto-
chemistry. Analyses of skin showed ATF4 staining in vascular
endothelial cells in mouse skin after 1 week of Poly(I:C) infusion,
and no staining in PBS infused skin. Unfortunately there were only
few visible vessels in the sections analyzed (Fig. 4f).
ATF4 is Required for the Upregulation of ET-1 in
Response to HLA-B35/ER Stress and Poly(I:C) in HDMECs
In order to determine whether ATF4 is directly involved in the
regulation of ET-1 gene we employed a siRNA approach to knock
down ATF4. Initial experiments established an optimal dose and
Figure 3. ER stress and Poly(I:C) activate ATF4 nuclear translocation and enhance phosphorylation of PERK and eIF2a. ATF4, pPERK/
PERK, and p-eIF2a/eIF2a protein levels in HDMECs after treatment with 10pM TG (a), 2.5 mg/ml Poly(I:C) (b), or transduction with 10 MOI of HLA-B35 or
HLA-B8 Ads for 48 hours (c). 20 mg of nuclear extract were separated via 15% SDS-PAGE for ATF4 and 10% SDS-PAGE for ATF6. 20 mg of total cellular
proteins were separated via 15% SDS-PAGE for pPERK/PERK and 10% SDS-PAGE for peIF2a/eIF2a, then transferred to a nitrocellulose membrane. The
blots were probed overnight with primary Abs at 4uC. As a control for equal protein loading, membranes were stripped and reprobed for Lamin A/C
or b-actin. Representative blots from at least three independent experiments are shown.
doi:10.1371/journal.pone.0056123.g003
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Figure 4. Poly(I:C) induces ET-1 gene through the PKR-dependent activation of the eIF2a/ATF4 pathway. 80% confluency, HDMECs
were treated with 20 nM PKR siRNA (siSCR) with or without Poly(I:C) treatment (a and b). Total RNA was extracted and mRNA level of PKR (a) and
PPET1 (b) were quantified by quantitative RT-PCR. Expression of the housekeeping gene b-actin served as an internal positive control in each assay
performed. After measurement of the relative fluorescence intensity for each sample, the amount of each mRNA transcript was expressed as
a threshold cycle value. 20 mg of nuclear extract were separated via 15% SDS-PAGE for ATF4 (c), 20 mg of total cell lysate were separated via 10% SDS-
PAGE for peIF2a/eIF2a (d), then transferred to a nitrocellulose membrane. The blots were probed overnight with primary Abs at 4uC. As a control for
equal protein loading, membranes were stripped and reprobed for Lamin A/C or b-actin. Representative blots of at least three experiments are
shown. (e) Expression of ATF4 by real-time PCR analysis of skin mRNA from C57B1/6 WT (n = 10), C57B1/6 IFNAR12/2 (n = 8) and C57B1/6 TRIF/TICAM
2/2 (n = 6) mice 1 week after subcutaneous insertion of osmotic pumps containing Poly(I:C). Fold-change shown in the graphs is normalized to
mRNA expression by one of the control mice. *p =0.05; **p = 0.001 (f) ATF4 protein expression in dermal biopsies obtained from C57Bl/6 WT mice 1
week after subcutaneous insertion of osmotic pumps containing Poly(I:C) or PBS (as control), and processed for immunohistochemistry as described
under Methods. Representative images of microvessels from PBS and Poly(I:C) skin is shown. Bar: 20 mm, 10 mm.
doi:10.1371/journal.pone.0056123.g004
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Figure 5. ER stress and Poly(I:C) upregulate ET1 via ATF4. 80% confluency, HDMECs were treated with 20 nM ATF4 siRNA (or siSCR) prior to
treatment with HLA-B35 (HLA-B8), TG, or Poly(I:C). Total RNA was extracted and mRNA level of ATF4 (a) and PPET-1 (b) were quantified by quantitative
RT-PCR. Expression of the housekeeping gene b-actin served as an internal positive control in each assay performed. After measurement of the
relative fluorescence intensity for each sample, the amount of each mRNA transcript was expressed as a threshold cycle value. (c) ET-1 protein was
measured by ELISA in the supernatants (n = 2). The average ET-1 protein concentration for each group is represented as a bar 6 SE. *p =0.05; **p
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time for the ATF4 siRNA to achieve maximal inhibition of
endogenous ATF4 mRNA level. Treatment of HDMECs with
20 nM ATF4 siRNA for 48 hours resulted in depletion of ATF4
mRNA levels (up to 50–60%) (Fig. 5a). Under these conditions
basal expression levels of ET-1 mRNA and protein were also
consistently decreased by ,30% (Fig. 5c and d). Following 24
hour incubation with siRNA, cells were treated with Ad-B35/GFP
(or Ad-B8), TG and Poly(I:C) for additional 24 hours. Depletion of
ATF4 completely abolished upregulation of ET-1 mRNA (Fig. 5b)
and protein (Fig. 5c) in response to these treatments, suggesting
that ATF4 is required for these responses.
We next examined the distribution of ATF4 protein in the
human skin by immunohistochemistry. Analyses of skin micro-
vessels showed heteregoneus distribution of ATF4, with some
vessels exhibiting strong endothelial cell nuclear staining, while
other vessels were negative for ATF4 (Fig. 5d). The number of
positive vessels also varied between different individuals. Because
patients with SSc have elevated circulating levels of ET-1 [20] we
also analyzed skin samples obtained from 19 patients with limited
cutaneous SSc (lcSSc), including 8 patients with PAH (lcSSc-
PAH), and 11 lcSSc-noPAH. Similar to healthy control skin,
endothelial cell expression of ATF4 varied between the patients,
however there was no overall difference in the intensity or staining
pattern between lcSSc and healthy individual biopsies. We did not
have information regarding the level of circulating ET-1 or the
presence of HLA-B35 antigen in this group of patients. Together,
these data indicate that ATF4 is highly expressed in a subset of
dermal microvessels, where it is likely involved in responses to
various environmental stimuli.
JNK and NF-kB Contribute to the ER Stress and Poly(I:C)
Induction of ET-1
JNK and NF-kB pathways have been previously reported to
contribute to the ET-1 gene expression in response to various
stimuli [4,5]. To determine if JNK and NF-kB contribute to the
upregulation of ET-1 in response to ER stress and TLR3 agonists,
cells were treated with HLA-B35, TG, and Poly(I:C) in the
presence or absence of the pharmacological inhibitors of these
pathways. Treatment with JNK inhibitor (SP6001, 25 nM)
resulted in down regulation of the basal and agonist-induced
PPET-1 mRNA levels (Fig. 6a, top panel). On the other hand,
basal expression of PPET-1 mRNA was not affected by the NF-kB
inhibitor (SN50, 25 nM), however stimulation of PPET1 by HLA-
B35, TG, and Poly(I:C) was completely inhibited (Fig. 6b, top
= 0.001. (d) ATF4 protein expression in human skin microvessels. Lesional skin biopsies were obtained from patients with lcSSc (with and without
PAH) and healthy controls, and processed for immunohistochemistry as described under Methods. Representative images of microvessels from
healthy control and lcSSc patients are shown; similar immunostaining pattern was observed in control and lcSSc skin biopsies. Bar: 50 mm, 10 mm.
doi:10.1371/journal.pone.0056123.g005
Figure 6. JNK and NF-kB contribute to the ER stress and Poly(I:C) induction of ET-1. Cells were treated with 25 nM of JNK (a) or NF-kB (b)
inhibitors for 3 hours before HLA-B35 (HLA-B8), TG, or Poly(I:C) treatments. Total RNA was extracted and mRNA levels of PPET-1 were quantified by
quantitative RT-PCR (top panel). ET-1 protein was measured by ELISA in the supernatants (bottom panel). The average protein concentration for each
group (n = 2) is represented as a bar 6 SE *p = 0.05; **p = 0.001.
doi:10.1371/journal.pone.0056123.g006
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panel http://www.nature.com/jid/journal/v128/n8/full/
jid200839a.html - fig. 1). Similar results were observed at the
protein levels (Fig. 6a and b, bottom panels). Interestingly, while
stimulation of ET-1 by HLA-B35 or TG was similarly affected by
the inhibitors of the JNK and NF-kB pathways, Poly(I:C)
stimulation of ET-1 was particularly sensitive to depletion of the
NF-kB pathway, suggesting that NF-kB plays a predominant role
in activation of the ET-1 gene by Poly(I:C) in HDMECs.
ATF4/c-JUN Complexes Mediate ET-1 Induction by ER
Stress and Poly(I:C)
ET-1 gene promoter contains binding sites for a number of
transcription factors, however using bioinformatics tools we were
unable to locate consensus ATF4 binding site within the promoter
region. Based on the previous report identifying ATF4 as a partner
of c-JUN in a two-hybrid screen [21], we asked whether ATF4
could form protein complexes with c-JUN in HDMECs. As shown
in Fig. 7a, ATF4/c-JUN complexes were present in unstimulated
cells and were increased upon stimulation with HLA-B35, TG,
and Poly(I:C). While, we could also detect formation of the ATF/
NF-kB complexes in unstimulated cells, formation of these
complexes was not affected by the agonists (Fig. 7b), suggesting
that formation of the ATF4/c-JUN complexes is not simply driven
by the elevated levels of ATF4 in stimulated cells.
We next utilized human ET-1 promoter constructs consisting of
the 2650/+172–bp fragment fused to the luciferase reporter gene
to confirm functional role of ATF4 in regulation of the ET-1 gene.
Transcriptional activation of the ET-1 promoter was observed
after treatment with HLA-B35, TG, and Poly(I:C) (Fig. 7c). To
analyze whether AP1 binding site was required for the regulation
of ET-1 transcription, cells were transfected with the 193-bp ET-1-
prom-luc construct (wild type) or the same construct carrying
mutated AP-1 binding site. As shown in Fig. 7d, mutation in the
AP1 binding site reduced the ER stress and Poly(I:C) induction of
the ET-1 promoter. These results support the functional role of the
AP1 complex in the ER stress and Poly(I:C)-mediated induction of
the ET-1 gene expression.
Discussion
In this study we show for the first time that ATF4 is a novel
regulator of the ET-1 gene in endothelial cells. ATF4 contributes
to the basal expression of ET-1 and is required for the induction of
ET-1 in response to both ER stress and dsRNA. Our results
strongly suggest that activation of the eIF2a/ATF4 pathway leads
to increased formation of the ATF4 protein complexes with c-
JUN, which, in turn, activate ET-1 transcription through the AP1
response element. ER stress inducers, including HLA-B35 and
TG, as well as dsRNA, also upregulate mRNA and protein
expression of ATF4, thus further amplifying this signaling pathway
Figure 7. Transcriptional upregulation of ET-1 by ER stress and Poly(I:C) is mediated through the ATF4/cJUN complex. Cell lysates
from the HLA-B35 (HLA-B8), TG, or Poly(I:C) treated HDMECs were immunoprecipitated with cJUN (a) or NF-kB p65 antibodies (b) and then analyzed
for ATF4 by western blot. Cells were transfected with the luciferase reporter driven by the 2650/+172–bp fragment of the human ET-1 promoter (c)
or with the 2193-bp ppET-1-prom-luc construct (wild type) or constructs with specific mutations in the AP-1 binding site (d). 24 hours post
transfection with the indicated plasmids, cells were stimulated with HLA-B35 (HLA-B8) Ads, TG and Poly(I:C) for an additional 24 h. Transfections were
normalized using pSVgalactosidase control vector. Basal and induced luciferase activity was measured by luminometry. The graph represents fold
change in promoter activity in response to various treatments in comparison with control promoter, which was arbitrarily set at 1. (e) Schematic
diagram showing PKR and PERK induced activation of the eIF2a-ATF4 axis followed by the protein complex formation with c-JUN and induction of
the ET-1 gene transcription through the AP1 response element.
doi:10.1371/journal.pone.0056123.g007
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(see diagram, Fig. 7e). Additional experiments show that NF-kB,
which is also activated by the ER stress and dsRNA in HDMECs,
contributes to the activation of ET-1 gene expression. Interest-
ingly, although, ATF4 forms protein complexes with NF-kB in
HDMECs, formation of these complexes was not increased by the
stimuli used in our study. Since NF-kB plays a key role in
activation of the ET-1 gene by cytokines, it is possible that the
ATF4/NF-kB complexes are involved in those responses.
Together, this study identifies ATF4 as a key mediator of ET-1
gene activation in response to cellular stress.
ATF4 is a short-live, basic region-leucine zipper (bZip) protein
that belongs to a family of the ATF/CREB transcription factors
[22]. Under normal physiological conditions translation of the
ATF4 protein is inefficient due to the presence of a short open
reading frame in its 59 untranslated region; however ATF4 protein
translation is facilitated by various stress conditions that trigger
global inhibition of protein synthesis [22]. Such conditions,
including ER stress, viral infection, nutrient starvation, and low
levels of heme induce activation of distinct protein kinases that in
turn lead to phosphorylation of a common downstream mediator,
eIF2abresulting in translational repression. The known kinases
that phosphorylate eIF2a include ER stress induced PERK,
dsRNA induced PKR, as well as GCN2 (general control non
repressed 2) and heme regulated inhibitor, HRI [22]. Here we
show that stimulation of ET-1 in response to Poly(I:C) is mediated
by PKR. In a related study Gargalovic et al have reported
activation of the eIF2a-ATF4 in human atherosclerotic lesions and
in cultured aortic endothelial cells exposed to oxidized phospho-
lipids [10]. The authors demonstrated that ATF4 contributed to
the upregulation of several inflammatory cytokines in cultured
aortic endothelial cells. ATF4 was also upregulated by herpesvirus
8 infection and contributed to proangiogenic response via MCP1
upregulation [23]. Furthermore, rapid induction of ATF4 has
been observed in smooth muscle cells (SMCs) in the medial
compartment of balloon injured rat carotid arteries [24].
Additional studies with cultured SMCs have demonstrated that
Fibroblast growth factors (FGF)-2 and mechanical injury stimulate
ATF4 levels, and that ATF4 is required for the FGF-2 mediated
upregulation of Vascular endothelial growth factor (VEGF)-A
[24]. Our study indicates that ET-1 is among the target genes
positively regulated by the eIF2a-ATF4 axis in response to ER
stress in endothelial cells. Collectively, these studies support a key
role for the eIF2a-ATF4 pathway in response to vascular injury
[25].
TLR3 is recognized by viral double-stranded RNA (dsRNA) or
its synthetic analog, Poly(I:C), and is expressed on the cell
membrane or in the intracellular vesicles, depending on the cell
type [26,27]. Ligand binding to the dimerized TLR3, leads to
recruitment of an adaptor protein TRIF/TICAM, which func-
tions as a platform for binding of additional signaling molecules
and activation of type I interferon and NF-kB pathways [27].
Previous studies have shown that activation of TLR3 signaling is
harmful to endothelial cells by promoting inflammatory and
atherogenic response in vitro and causing impairment of vessel
regeneration in vivo [28]. Elevated levels of TLR3 were found on
fibroblasts, immune and endothelial cells in SSc skin biopsies, thus
implicating this pathway in the pathogenesis of SSc [29,30]. This
study extends previous work from our group that demonstrated
activation of the markers of vascular injury by dsRNA/Poly(I:C)
and potential role of the TLR3 signaling to the pathogenesis of
SSc [16]. Several studies have shown that activation of the TLR3
signaling pathway leads to impairment of the endothelial cell
function including activation of proinflammatory and pro-athero-
sclerotic mechanisms [31,32]. ER stress/UPR, as well as the
activation of the innate immunity pathways has been implicated in
the pathogenesis of several inflammatory diseases [9,12], however
the role of these pathways in PAH and in SSc-related vasculopathy
has not yet been explored.
Endothelial cells constitute a first line of defense protecting
tissues from injury. Elevated production of ET-1 is a common
characteristic associated with endothelial cell dysfunction in
various pathological conditions, including pulmonary arterial
hypertension [33]. Previous studies have shown that HLA-B35 is
associated with an increased risk for developing PAH in patients
with scleroderma (SSc) [15]. The current study further supports
the potential pathogenic role of HLA-B35 in upregulating ET-1
production and clarifies the molecular mechanism involved in this
process in endothelial cells. In addition, this study raises an
intriguing possibility that chronic activation of the eIF2a/ATF4
pathway could contribute to the disease pathogenesis. Although,
we were able to demonstrate, activation of ATF4 in selected skin
biopsies of patients with lcSSc, absence of full clinical data,
including levels of circulating ET-1 and presence of HLA-B35
antigen, precluded proper analyses of these samples. This
limitation may be addressed in future studies with a larger set of
fully characterized samples from patients with lcSSc.
Supporting Information
Figure S1 Treatment with mouse monoclonal anti-MHC
class I blocking antibody did not affect ET-1 and ATF4
mRNA levels in HDMECs transfected with HLA-B35.
PPET-1 (right panel) and ATF4 (left panel) mRNA after HLA-B35
(or HLA-B8) treatments with increasing dose of mouse mono-
clonal anti-MHC class I blocking antibody (W6/32) in HDMECs.
Confluent dishes of HDMECs were transduced with 10 MOI of
Adenovirus encoding HLA-B35/GFP (Ad-HLA-B8/GFP) for
24 h and then with increasing dose of W6/32 (0.1–10 mg/ml)
for the following 24 hours. Total RNA was extracted and mRNA
levels of PPET-1 and ATF4 were quantified by quantitative RT-
PCR. Expression of the housekeeping gene b-actin served as an
internal positive control in each assay performed. After measure-
ment of the relative fluorescence intensity for each sample, the
amount of each mRNA transcript was expressed as a threshold
cycle value.
(TIF)
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